Jim Simons Cyteir Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.71 - $2.84 $95,259 - $99,828	-35,151 Reduced 25.14%	104,649 $297,000
Q2 2023 Aug 11, 2023	SELL	$1.74 - $2.6 $63,047 - $94,208	-36,234 Reduced 20.58%	139,800 $363,000
Q1 2023 May 12, 2023	SELL	$1.47 - $1.84 $78,143 - $97,812	-53,159 Reduced 23.19%	176,034 $320,000
Q4 2022 Feb 13, 2023	SELL	$1.18 - $1.76 $44,401 - $66,225	-37,628 Reduced 14.1%	229,193 $378,000
Q3 2022 Nov 14, 2022	SELL	$1.99 - $4.05 $160,236 - $326,110	-80,521 Reduced 23.18%	266,821 $512,000
Q2 2022 Aug 12, 2022	BUY	$1.62 - $4.4 $404,258 - $1.1 Million	249,542 Added 255.16%	347,342 $1.04 Million
Q1 2022 May 13, 2022	BUY	$3.39 - $10.51 $242,724 - $752,516	71,600 Added 273.28%	97,800 $369,000
Q4 2021 Feb 11, 2022	BUY	$9.83 - $19.21 $257,546 - $503,302	26,200 New	26,200 $298,000

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.